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ABSTRACT 
Introduction 
The emergence of multi-drug resistant bacteria has led to higher treatment failure and a subsequent 
increase in patient mortality. Limited treatment options are available for Gram-negative bacteria (GNB) 
that are resistant to carbapenam antibiotics. Colistin is considered as the last resort treatment options for 
the carbapenamase producing GNB, though occasional reports of colistin resistance has been noted in the 
literature. Available studies show efficacy with both doses and with variable levels of adverse effects. In 
the absence of consensus regarding a dosing strategy for colistin, a model comparing low and high dose 
colistin in the treatment of nosocomial pneumonia will serve as a useful tool in decision making. 
 
Methods 
A decision–analytic model using data obtained from a retrospective review of patients treated for 
nosocomial pneumonia at King Abdulaziz Hospital, Saudi Arabia, was developed to compare the costs 
and outcomes of low dose versus high dose colistin in the treatment of nosocomial pneumonia caused by 
colistin-only sensitive bacteria. Outcome measures used in the analysis were length of antibiotics use, 
length of hospital stay, cure and nephrotoxicity in order to calculate the mean total cost of treatment, 
incremental costs, cost effectiveness ratios and incremental cost effectiveness ratios. 
 
Results 
There was a total of 171 patients that received colistin during the study period of which 96 met the 
inclusion criteria. Of the remaining patients 33 received high dose and 63 received low dose colistin. Low 
dose colistin was associated with a non-significant 9% lower cure rate than high dose colistin (21% vs 
30%, respectively; p=0.292). Low dose colistin was associated with a 22% lower incidence of 
nephrotoxicity than HDC (30% vs 8%, respectively) which was found to be significant (p=0.004), 
respectively. Low dose colistin was associated with similar cure rates and greater cost savings resulting 
from nephrotoxicity being avoided compared to high dose colistin (ICER = -SAR 13, 894.66 per 
nephrotoxicity avoided). 
 
Conclusion 
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Low dose colistin was not inferior to high dose colistin in terms of clinical cure and had a lower incidence 
of nephrotoxicity resulting in significant cost avoidance.  The cost–benefit profile suggests that low dose 
colistin could be considered a more cost-effective option than high dose colistin in the treatment of 
patients with pneumonia caused by MDR-GNB in Saudi Arabia. King Abdulaziz Hospital should adopt 
the low dose colistin strategy for treatment of nosocomial pneumonia caused by colistin-only sensitive 
gram negative bacteria while taking cognizance of local resistance patterns. 
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CHAPTER 1 
 INTRODUCTION 
 
1.1 INTRODUCTION 
Hospital Acquired Pneumonia (HAP) is the second most common nosocomial infection in United 
States(1). Rates of HAP due to multidrug-resistant gram-negative bacteria (MDR-GNB) have escalated in 
recent years and are a major concern(2). Gram negative pathogens are increasingly resistant to commonly 
used first line antibiotics and colistin is in most cases the only medicine available against MDR GNB. 
There are no definite dosing recommendations for colistin with very limited information available 
comparing the effectiveness of low versus high dose colistin. Given the reported efficacy of low dose 
colistin in the treatment of MDR GNB(3–5) and the financial burden that Nosocomial Pneumonia (NP) 
places on the healthcare systems worldwide, it makes good sense to construct an economic model that 
will allow for the comparison of low and high dose colistin in the treatment of pneumonia caused by 
colistin-only sensitive MDR GNB. This model will add significantly to the medical literature and assist 
healthcare professionals in making decisions related to colistin prescribing in critically ill patients. 
 
1.2 BACKGROUND AND RATIONALE 
1.2.1 Background 
Nosocomial Pneumonia (NP) is defined as pneumonia that occurs after healthcare contact. NP 
encompasses hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)(1,6). HAP 
is a lung infection that occurs in non-intubated hospitalized patients 48 hours or more after admission as 
compared to VAP which occurs 48 hours or more after endotracheal intubation. In  the United States of 
America, HAP is estimated to occur in 5 to 10 patients per 1,000 hospital admissions(1). The incidence of 
NP is up to twenty times greater in patients receiving ventilator support(7). The incidence of VAP 
according to the CDC National Healthcare Safety Network report of 2010 is between 0 and 5.8 per 1,000 
ventilator days(8). The incidence of  VAP in developing countries, however,  ranges from 16.7 to 73.4 per 
1,000 ventilator-days in adult ICUs(9,10). 
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For HAP outside the intensive care unit, the mortality is reported to be up to 27.7%(11) and mortality due 
to VAP, on the other hand has been reported between 24% and 76% depending on the causative 
organism(12,13). El-Saed et al found that the rates of VAP in three Arabian countries was 4.8/1000 
ventilator days(14). The financial burden due to VAP is greater than other nosocomial infections(15) and 
according to the World Health Organization (WHO), Healthcare Associated Infections (HCAI) contribute 
16 million extra days to hospital stay in Europe. The direct cost associated with the disease is 
approximately $7 billion. In 2004, the cost of HCAI in the US translated into approximately US$ 6.5 
billion(16). Estimates of the costs of VAP per patient; range from $12,000 to $25,000. The effect of MDR 
bacterial infections have been studied and demonstrate an increase in overall costs(17).  
 
Bacterial causes of HAP may include Klebsiella Pneumonia (KP), Enterobacter, Serratia (KES), 
Pseudomonas Aeruginosa (PA), Acinetobacter species (AB), Stenotrophomonas maltophilia, 
Burkholderia cepacia, Methicillin Sensitive Staphylococcus aureus (MSSA) and Methicillin resistant 
Staphylococcus aureus (MRSA), Haemophilus influenzae, Streptococcus pneumoniae and Legionella 
pneumophila. Of these MRSA and gram-negative bacilli are the most common bacterial causes of HAP. 
MRSA frequently causes nosocomial pneumonia, and though this is problematic for the clinician, there 
are a number of available options such as linezolin and ceftaroline. 
 
Gram negative pathogens are increasingly resistant to commonly used first line antibiotics. The increasing 
incidence of pneumonia in critically ill patients caused by MDR-GNB resistant to carbapenem antibiotics 
means that treatment options are quite limited for such patients(2,18,19). MDR-GNB for the purposes of 
this study is defined as bacteria resistant to aminoglycosides, anti-pseudomonas penicillins, carbapenems, 
cephalosporins and fluoroquinolones. 
 
Colistin is perhaps one of a few and in most cases the only medicine available against MDR GNB and is 
recommended by the ATS guidelines(20). Colistin, also known as Polymixin E, is a relatively old 
antibiotic that was abandoned due to high risk of nephron- and neurotoxicity(21). Despite the toxicities, 
this old medicine has recently gained favor due to nosocomial infections caused by the emergence of 
GNB susceptible to colistin(22). Colistin is administered as a pro-drug, colistin methansulphonate(23), 
which is then converted in the body into the active colistin. Colistin possesses a narrow antibacterial 
spectrum and is effective against PA, AB and KP(23,24). 
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Commercially, colistimethate sodium (CMS) is available in 2 forms, namely Colomycin ® (Europe) and 
Coly-Mycin M ® (USA). Colistin 1mg base is equivalent to approximately 2.4 mg of colistimethate 
sodium. CMS has a potency of 12,500 IU/mg(22). 
 
Intravenous colistin as Colomycin ® (colistimethate sodium) contains 1 million international units (MIU) 
powder/vial equivalent to 30,000IU/mg(3). Coly-Mycin M® contains 4.5 million international units 
(MIU) equivalent to 150 mg colistin base(25). The recommended dose for both these preparations vary 
greatly; Colomycin® 1.5-2.5 mg /kg/d and for Coly-Mycin M® 2.5-5 mg/kg/day(21). 
 
With concerns surrounding the development of resistance to one of the last resorts against MDR-GNB, 
there is a huge debate mostly in favor of high dose colistin(21). Recently, doses as high as 10 mg/kg/day 
have been used(4). However, significant literature exists regarding low dose colistin with comparable 
effectiveness(4,5). Still, there are however, no definite dosing recommendations and limited information 
is available about the comparative effectiveness of low versus high dose colistin. 
 
Nephrotoxicity is one of the most commonly cited adverse effects of colistin treatment(18,26–28). A 
number of factors have been associated with colistin induced nephrotoxicity, such as concomitant 
nephrotoxic medications(26)
,
(29), body weight(28), hypoalbuminemia(29), advanced aged(29), colistin 
dose(4) and duration of treatment(27). For this study, the following definition for nephrotoxicity due to 
colistin was used; increase in serum creatinine by 0.3mg/dL (26.52 µmol/L) or more within 48 hours or 
increase in serum creatinine to 1.5 times baseline or more within the last 7 days(30). 
Given the reported efficacy of low dose colistin in the treatment of MDR GNB(3–5) and the financial 
burden that NP places on healthcare systems worldwide, it is logical to construct an economic model that 
will allow the comparison of low and high dose colistin in the treatment of pneumonia caused by colistin-
only sensitive MDR GNB. Such a model would be able to capture all clinical outcomes using a 
probability based decision tree to gauge the benefit and/or harms associated with low dose versus high 
dose colistin.  
 
1.2.2 Medical expenditure 
 
Medicine expenditure is growing globally. This is well reflected by the fact that prescription medicine 
expenditures in United States have more than doubled over the last decade; US spent $120 billion on 
prescription medicines in the year 2000 compared to $263 billion in 2011(31). Similar increasing trends 
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have been observed across the world where pharmaceutical expenditures per capita in Organization for 
Economic Co-operation and Development countries have consistently increased over the period of 2008-
2013(32). Given the growing pressures of cost containment initiatives arising from global financial crisis, 
funding decisions are increasingly based on objective analysis of pharmacoeconomic data. Funding 
bodies in United Kingdom(33) and Australia(34) require pharmacoeconomic and budget impact analysis 
data at the time of submission for new Health Technology Applications. 
 
The most recent (2007) inflation adjusted US estimates of the cost of health care associated infections 
derived from 1992 data are in the region of US$6.65 billion(15). The economic impact of NP on hospital 
costs is significant and even greater in patients who develop VAP(6,35). According to the WHO, 
estimates of the overall extra costs in ICU for Nosocomial pneumonia is US$2255 per case in some 
developing countries(35). Studies have also reported on the significant increase in hospital costs as a 
result of drug-resistant pathogens(36,37). 
 
Given the impact of NP in terms of mortality, length of ICU and hospital stay, added costs and the paucity 
of information on cost effectiveness of colistin in the treatment of NP caused by colistin only sensitive 
GNB, such information will add significantly to the medical literature. Studies on the safety and efficacy 
of colistin abound both with high(24,38) and low doses(3–5). Studies have shown efficacy with both 
these doses with variable level of adverse effects. The absence of a definite dosing strategy makes a 
model to compare low and high dose Colistin in the treatment of pneumonia caused by colistin-only 
sensitive MDR-GNB invaluable in assisting clinicians, hospitals and insurance agencies in making 
decisions regarding the appropriate use of colistin in critically ill patients. 
 
1.2.3 Principles of Pharmacoeconomics 
 
Pharmacoeconomics (PE) is an established discipline of Health Economics. Several definitions exist for 
PE but in simple terms, it is a scientific discipline that compares the value of one pharmaceutical agent, 
service or programme to another to make a conclusion about the preferred choice from a payer, societal or 
an individual perspective. 
 
There are four economic evaluations that are used, namely, Cost Minimization Analysis (CMA), Cost 
Benefit Analysis (CBA), Cost effectiveness analysis (CEA) and Cost Utility Analysis (CUA). CMA 
compares two therapeutically equivalent treatment alternatives to determine the least costly. CBA 
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compares the benefits and costs of treatment alternatives. The benefits and costs are measured and 
converted to equivalent dollars and expressed as a benefit to cost ratio. 
CEA compares two treatment options for which there is no evidence to support equivalence in safety and 
efficacy. Costs are measured in dollars and outcomes are measured in nonmonetary terms e.g. lives saved 
or cases cured. The results of a CEA are expressed as Incremental Cost Effectiveness Ratio (ICER) which 
is the ratio of health care costs divided by the clinical outcome. CEA therefore deals with cost 
optimization as compared to cost reduction for CMA. 
 
CUA compares treatment alternatives that include patient preference and health related quality of life 
(HRQOL). Results of CUA are expressed as a ratio of cost versus utility. Cost-effectiveness analysis is 
one type of PE analysis that identifies the most economical option when efficacy and safety of 
comparisons is not similar. Outcomes are measured as increase in effectiveness delivered for each dollar 
invested. 
 
This study, using the ICER, is intended to assist in containing healthcare costs without adverse health 
consequences. Conducting an ICER requires that the two interventions have different efficacy and safety 
profile. This was tested in this study prior to an assessment of costs. In PE, an assessment of costs 
depends on the perspective of the study and these may include the patients, providers, payer and society. 
The patient perspective considers all costs incurred by the patient for the healthcare services received and 
the consequences are more subjective and may include cure or Quality of Life (QoL). The societal 
perspective considers all costs (direct and indirect) and considers all consequences including QoL. The 
payer perspective considers cost of delivering the healthcare service and includes personnel and supply 
costs and considers consequences such as LoS and mortality. This study considered the perspective of the 
payer with regards to cost and consequences. 
 
The costs include only direct medical costs which relate to administration costs, healthcare provider costs, 
hospitalization costs, laboratory tests and the cost of medication. In this analysis from a payer’s 
perspective, indirect medical costs such as transportation; indirect non-medical cost such as lost income; 
and intangible costs such as pain are not considered.  Figure 1 provides an outline of PE analysis 
conducted. 
 
Due to various uncertainties that may arise when performing PE analyses, sensitivity analyses may be 
used to test the conclusions of the study when these depend on certain assumptions(39). One-way 
sensitivity analyses allow for the evaluation of the impact of one parameter on the conclusion of the 
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study. This is done by allowing one variable to be adjusted while keeping the others at the baseline. This 
allowed for an assessment of which parameters will likely have the greatest impact on the conclusions. 
 
 
 
 
1.3 Research questions 
 
This study focused on the following research question: 
Is low dose Colistin more cost effective than high dose Colistin in the treatment of Pneumonia caused by 
Colistin-only sensitive gram Negative Bacteria 
 
1.4 Aims and objectives 
 
Figure 1: Decision Tree 
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This study aims to determine the cost effectiveness of low dose versus high dose Colistin in the treatment 
of Pneumonia caused by Colistin-only sensitive MDR-GNB at a tertiary care hospital in Saudi Arabia. 
 
By the end of the study period, the objectives were to: 
1. Calculate and compare the clinical cure rates of low dose Colistin (LDC) and high dose Colistin 
(HDC) for the treatment of nosocomial pneumonia (NP) due to colistin-only sensitive multi-drug 
resistant gram –negative bacteria (MDR-GNB). 
 
2. Calculate and compare the incidence of nephrotoxicity in patients receiving LDC and HDC for NP 
caused by colistin-only sensitive MDR-GNB. 
 
3. Propose an outcome-based economic model to compare LDC and HDC for NP caused by colistin-
only sensitive MDR-GNB. 
 
1.5 Significance of the study 
 
HAP due to MDR-GNB has escalated in recent years and is a major concern(2). The increasing incidence 
of pneumonia in critically ill patients caused by MDR-GNB resistant to Carbapenems limits available 
treatment options (2,18,19).  
In the Kingdom of Saudi Arabia (KSA) there are some studies on incidence of VAP. Memish ZA, et al 
described the incidence of VAP in a tertiary hospital in Riyadh Saudi Arabia and found the incidence to 
be 16.8/1000 ventilation days. The most common GNB responsible were Pseudomonas then 
Acinetobacter species(40,41). A more recent study by El-Saed et al found that the combined incidence of 
VAP in three Middle Eastern countries was 4.8/1000 ventilator days(14). This study did not report on the 
pathogens that were responsible. 
 
To the best of our knowledge, there are no studies reporting on models for the cost effectiveness of low 
and high dose of intravenous colistin in the treatment of colistin-only sensitive MDR-GNB. This study is 
intended to clarify the appropriate safe and effective dosing of colistin in the treatment of colistin-only 
sensitive MDR GNB and assist healthcare professionals in making decisions related to colistin 
prescribing in critically ill patients. 
 
Such an analysis would be able to capture all clinical outcomes using a probability based decision tree to 
gauge the benefit and/or harms associated with low dose and high dose colistin. Furthermore, such an 
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economic model will add significantly to the medical literature and assist healthcare professionals in 
making decisions related to colistin prescribing in critically ill patients. This will also be beneficial to 
antimicrobial stewardship programs in their efforts to contain healthcare costs and minimize adverse 
health consequences.  
1.6 Research Methodology 
 
1.6.1 Study design 
This study is a retrospective, single-centre cohort design, using cost effectiveness analysis. A 
pharmacoeconomic model was developed to compare the cost-effectiveness of low versus high dose 
colistin in the treatment of nosocomial pneumonia caused by MDR-GNB at King Abdulaziz Hospital, 
AlHasa, Saudi Arabia. All patients receiving colistin for the treatment of nosocomial pneumonia from 
July 2011 to December 2014 were included in the study. The economic evaluation was conducted from 
the perspective of King Abdulaziz Hospital and only direct costs, obtained from the hospital business 
centre 2016 price list, were included in the study. 
 
1.6.2 Data Collection 
A standardized case form was used to record patient characteristics, including age, gender, weight, ICU or 
non- ICU location, renal function, underlying comorbidities using the Charlson comorbidity index, 
concomitant medications that may be potentially nephrotoxic, causative organism, daily dose of colistin, 
frequency and duration of colistin therapy, cumulative dose of colistin, clinical response to therapy 
(defined as resolution of signs and symptoms of infection including absence of fever for a minimum of 72 
hours and a white blood cell count below 12 000 cells/ mm
3)
),  duration of hospitalization and incidence 
of acute kidney injury. 
 
1.6.3 Data source 
Data was extracted from the electronic records of the Health Information Managements system as well as 
paper medical records maintained by the Health Information Management department. Records were 
searched from July 2011 to December 2014 and included all patients treated with colistin. This was then 
cross referenced with all patients treated for nosocomial pneumonia during the same period. Patients were 
matched as per inclusion and exclusion criteria. Data was initially collected on the case form and 
subsequently imported into Microsoft® Excel. Data abstractors that have previous experience with the 
management of data were oriented to the requirements of the study data but remained blind to the study 
aims and objectives. 
 
21 | P a g e  
 
1.6.4 Data Analysis 
The primary objectives were to calculate and compare the clinical cure rates (efficacy) and incidence of 
colistin induced nephrotoxicity (safety). The data was modelled using a decision analysis and each 
outcome on this model was assigned a cost with the help of hospital business center. Incremental cost 
effectiveness ratio was calculated for each option considering clinical cure and colistin induced 
nephrotoxicity. 
For all statistical analyses, two-sided significance was used. All p values of 0.05 or less were considered 
statistically significant providing a 95% confidence interval. Dichotomous data were compared using the 
Chi-Square test. Normally distributed continuous data were expressed as mean and standard deviation and 
compared using the Student’s t-test. Otherwise, values were presented as medians with ranges and were 
compared using the Mann – Whitney test. Quantitative variables were analyzed with the chi square test or 
Fischer’s exact test (two-tailed) when necessary. All data was entered in a database and IBM® SPSS® 
20.0 software was used to analyze the data. 
 
1.6.5 Data Management 
Raw data was imported into Microsoft® Excel. All computers are password protected. Only the primary 
investigator and data abstractors had access to the data stored on the computer. Data was shared with 
supervisors via a Dropbox folder that is password protected and the password was only shared with the 
supervisors. Data will be stored for a period of 5 years on hard copy and Microsoft Excel and then 
shredded/deleted. 
 
1.6.6 Ethics Approval 
The study was conducted in accordance with the principles of the Declaration of Helsinki and its 
amendments and in compliance with International Conference on Harmonization, Good Clinical 
Practices, and all applicable regulatory guidelines.  
Full ethical approval for the study was obtained from King Abdullah International Medical Research 
Centre (HAS-16-437780-10741) on 19 January 2016 (Annexure 1) and from the Humanities and Social 
Sciences Research Ethics Committee of the University of KwaZulu-Natal (HSS/0975/015M) on 29 
January 2016 – (Annexure 2). Patient confidentiality was maintained at all times and no patient 
information was reported in the data sets. 
 
1.7 Chapter summary 
This chapter provided a background and rationale to the study.  
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The dissertation consists of four chapters as follows: 
 Chapter 1: Provides an introduction to the study as well as aims, objectives and a brief overview of 
the methodology. 
 Chapter 2: consists of the literature review 
 Chapter 3: Provides the results, discussion and conclusion written in manuscript format. 
 Chapter 4: provides the general conclusions, strengths, limitations of the study and 
recommendations. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
In order to conduct a cost effectiveness analysis (CEA), the efficacy and safety of the alternative 
medications must be considered. A literature review was conducted to justify the assumption that low 
dose and high dose colistin are not equivalent. Given the impact of NP in terms of mortality, length of 
ICU and hospital stay, added costs and the paucity of information on cost effectiveness of colistin in the 
treatment of NP caused by colistin-only sensitive GNB, such information will add significantly to the 
medical literature. 
 
2.2 LITERATURE SEARCH  
 
The following databases were searched: PubMed, Google Scholar, Science Direct and CINAHL 
(Ebscohost) using the following search terms: “cost effectiveness”, “efficacy”, “colistin”, 
“pneumonia”, “gram negative” and “multi drug resistant”. Searches conducted in Pubmed retrieved 118 
articles, 25 with the search terms “colistin AND pneumonia AND gram negative AND efficacy”; 2 with the 
search terms “colistin AND pneumonia AND cost effectiveness”; 12 with the search terms “colistin AND 
efficacy AND multi drug resistant” and 79 with the search terms “colistin AND gram negative AND 
efficacy”. Searches in Google Scholar retrieved 167 studies, Science Direct 862 studies and CINAHL 
(Ebscohost) 196 studies.  The titles were reviewed and irrelevant topics and duplicates were 
eliminated. The abstracts were then reviewed and those meeting the inclusion criteria were retrieved. A 
total of 38 studies matching our inclusion criteria were retrieved. All studies were in English language. 
 
2.3. LITERATURE REVIEW OF COLISTIN 
 
2.3.1 Effectiveness of high dose colistin 
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In a retrospective study by Kalin et al(4) on 45 patients comparing doses less than 5mg/kg/day (low), 
5mg/kg/day (normal dose) and 10 mg/kg/day (high dose) colistin in the treatment of VAP caused by 
Acinetobacter Baumannii (AB), the clinical response at the end of therapy was 30% in the low and 
normal dose groups and 7% in the high dose group. Mortality was higher in the high dose group at 67% 
compared to 40% in the low dose group and the authors concluded that high dose colistin has no benefit 
in the treatment of VAP caused by AB. This was a small sample that was further confounded by the 
severity of the disease of the included cohort. The clinical response obtained by Kalin et al. are in contrast 
to another study (24) using doses between 2 and 10mg/kg/day in the treatment of infections due to MDR-
GNB where out of 60 patients, 71.7% had a favorable response. Subgroup analysis revealed that 69.4% of 
the patients with pneumonia had a favorable response. It must be noted that in this study colistin was used 
in combination with other antimicrobials and this was a heterogeneous sample with various infection 
types so it is rather difficult to assign the positive outcomes achieved solely to colistin. 
 
A small prospective, observational, cohort study(42) using 720mg/day (approximately 10mg/kg/day) 
colistin found that the higher doses achieved higher clinical cure i.e. 82.1% in all patients treated for 
sepsis due to GNB susceptible only to colistin. Clinical cure in VAP patients was 100% however the 
bacteriologic cure was attained in only 40% of these patients. Colistin was used as monotherapy in 50% 
of the cases. A major limitation of this study was the small sample size. A prospective study with a much 
larger sample (43) found that mortality was much higher amongst patient who received colistin (39%) 
compared to other antibiotics (28.8%). Notably the patients receiving colistin were very different from 
those receiving other antibiotics (age, MDR Klebsiella Pneumonia) and the doses used were much lower 
at approximately 2.5mg/kg/day. 
 
In a retrospective study of 121 patients (38) using daily doses ranging between 120-480 mg against MDR 
Pseudomonas Aeruginosa, a favorable clinical outcome was found in 65% of patients with pneumonia. In 
patients receiving more than 240mg/day, 85% achieved a favorable clinical response compared to 69.3% 
in patients receiving doses lower than 240mg/day however this was not statistically significant. 
Furthermore, mortality related to MDR pseudomonas in this study was 16.5%. The major difference 
between this and other studies is the inclusion of the majority of patients from non-ICU setting. The 
findings of this study concur with those of Dalfino et al (42) in that a better clinical response (73%) was 
observed when higher doses were utilized. 
 
Falagas et al (44) have also used doses up to 720mg/day and achieved higher rates of clinical response in 
the treatment of MDR-GNB. Furthermore this study found colistin to be more effective in the treatment 
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of pneumonia. Regimens of colistin alone or in combination with Meropenem also favored a better 
response compared to regimens containing colistin with other agents. Older patients and those with 
greater changes in renal function fared worse. Mortality among patients who received an average daily 
colistin dose of 240mg/day (3.4mg/kg/day) (38.6%) was higher than mortality among patients who 
received 480mg/day (27.8%) as well as those who received 720mg/day (21.7%). The mortality in the low 
dose group was similar to that reported by Paul et al (43) when doses of 2.5mg/kg/day were used. The 
mortality rates reported are however very different to those reported by Kalin et al (5) where mortality 
was much higher in the high dose group. Whereas Kalin et al studied VAP caused by Acinetobacter; the 
study by Falagas et al included various MDR-GNB at different sites. 
 
 
2.3.2 Effectiveness of low dose colistin 
 
As mentioned earlier, the study by Kalin et al (4) showed a higher clinical response (30%) in patients 
using doses less than 5mg/kg/day (low) compared to patients using the higher 10mg/kg/day in the 
treatment of VAP caused by Acinetobacter Baumannii (AB). The clinical response in the low dose group, 
although higher than that of the high dose group, was relatively low (30%) compared to some other 
studies and this can be attributed to the severity of illness of the study patients. 
 
Yilmaz et al (3) studied patients receiving colistin in doses ranging from 1.25 to 2.5 mg/kg/day for 
nosocomial infection due to colistin only sensitive pathogens and reported a clinical response rate of 
69.2%, a rate similar to that reported in some previous studies(45). Clinical and microbiological cure rates 
were similar as well. Another study (5) aiming to determine the bacterial cure rate of low dose colistin in 
MDR GNB, concluded that the low dose is effective. A bacterial cure rate of 75.2% was achieved and 
there was no statistical difference between the group that achieved and did not achieve cure in relation to 
dose or duration of colistin. A limitation of this study was that the possibility of colonization could not be 
excluded and so patients classified as infection may have been colonized. Both studies included patients 
that were not homogeneous in the site of infection. 
 
In a study investigating the clinical response of colistin in VAP caused by Carbapenem resistant 
Acinetobacter Baumannii response rates were similar between groups that were treated with monotherapy 
(72.7%) and combination therapy (78.8%)(45). Response for regimens containing colistin was 66.7%. 
Whether combinations would provide any additional benefit was unclear due to the small sample size 
however another study(38) failed to demonstrate any additional benefit when combining colistin with 
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other antimicrobials. This study was confounded by polymicrobial VAP and the use of concomitant 
antimicrobials. Furthermore, VAP was confirmed by different techniques for different patients and this 
could have affected the results. 
 
2.3.3 Nephrotoxicity associated with the use of colistin 
 
Nephrotoxicity is a most commonly cited adverse effects of colistin treatment (18,26–28) and numerous 
studies have reported on the factors associated with colistin induced nephrotoxicity (4,26,28,29). In a 
study by Montero et al (38), nephrotoxicity was reported as 8.3%. Colistin dose was not identified as an 
independent risk factor of nephrotoxicity however previous chronic renal impairment, diabetes mellitus, 
and the use of aminoglycosides were risk factors. On the other hand, an earlier study (27) reported a rate 
of nephrotoxicity of 14.3 % but noted a dose dependent relationship (higher doser, higher nephrotoxicity) 
that was statistically significant. The authors also noted a correlation between development of 
nephrotoxicity and duration of treatment. This study was confounded, however, by the administration of 
other potentially nephrotoxic medications which may have led to an overestimation of nephrotoxicity. It 
must be noted further that both these studies used slightly different definitions of nephrotoxicity. 
 
In another cohort (46), nephrotoxicity was reported as 43%. The authors identified doses greater than 
5mg/kg/day as an independent risk factor for nephrotoxicity (using RIFLE criteria). Furthermore, a trend 
towards greater nephrotoxicity was identified when colistin was dosed between 3mg/kg/day and 
4.9mg/kg/day. Aminoglycoside use was however not associated with an increase risk. In a later study(4) 
colistin in various doses was investigated in the treatment of VAP caused by Acinetobacter Baumannii. A 
dose response relationship was noted with higher doses up to 10mg/kg/day contributing to greater rate 
(40%) of nephrotoxicity. The severity of illness of this cohort may have contributed to the higher rates 
since the majority exhibited sepsis or septic shock (4). 
 
Another study(45) reported a much higher rate of colistin associated nephrotoxicity using doses between 
2.5 and 5mg/kg/day. The rate of nephrotoxicity was 18% however once other potentially nephrotoxic 
medication were excluded the rate in the colistin based group was 57.1%. This study was confounded by 
the presence of polymicrobial VAP treated with concomitant antibiotics as well as the use of polymixin B 
and colistin. Furthermore, the majority of patients were trauma victims and hence more critically ill. 
 
Dalfino et al (42) did not observe any deterioration of renal function in 82.1% of the cohort using a high 
dose strategy that was administered over extended intervals. In the patients whose renal function was 
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affected, they did not find any correlation between renal function and cumulative colistin dose or duration 
of treatment. Similar results were obtained in another prospective study using the same dosing strategy for 
colistin in the treatment of colistin-only susceptible GNB (47).  
Renal function was not affected in 83.87% of patients. In the patients that did develop nephrotoxicity, 
almost half had some pre-existing renal impairment. Both these studies were limited by the small samples 
and lack of control group. In a retrospective study (3) nephrotoxicity was reported as 7.7 % for patients 
that received low dose (approx. 1.25mg/kg/day) and 18.2 % for those that received high (2.5mg/kg/day) 
dose colistin. Although the rate of nephrotoxicity was greater with high dose colistin group, this was not 
statistically significant. It is plausible that due to the low sample size, this study was not powered to 
detect any significant difference. These results are in contrast to an earlier mentioned study(27) that 
reported a dose response relationship that was significant as well as a correlation with cumulative dose of 
colistin. Zaidi et al (5) in their investigation of the safety of low-dose (approximately 2mg/kg/day) colistin 
in the treatment for MDR-GNB infections reported a rate of nephrotoxicity of 12.8%. The rate of 
nephrotoxicity was independent of location in hospital (ICU or not) and similarly with the use of other 
potentially nephrotoxic medications, i.e. gentamycin, vancomycin, NSAIDs or ACE inhibitors. 
 
2.3.4 Cost-effectiveness studies in Nosocomial Pneumonia 
 
Models for cost effectiveness analysis are available for nosocomial pneumonia in general(48) and for 
methicillin-resistant Staphylococcus aureus(49,50), however there are significant differences with MDR 
NP. Currently no studies of colistin cost effectiveness could be found and thus there is an urgent need to 
study this aspect of NP. 
 
2.3.5 The role of Colistin use in Antimicrobial Stewardship 
  
Antimicrobial stewardship programs (ASP) are hospital based programs aimed at improving antibiotic 
use.  ASP can optimize treatment of infections and minimize antibiotic related adverse effects (51,52). 
ASP assists in improving quality of patient care(53) and improve patient safety by providing better cure 
rates(54,55). 
The introduction of ASP stemmed from the unavailability of newer drugs to treat GNB and the increase in 
MDR organisms. Inappropriate colistin dosing may lead to the emergence of resistance. (56) 
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The CDC in their 2006 guideline on “Management of Multi-Drug Resistant Organisms in Healthcare 
Settings” stated that control of multi-drug resistant organisms “must include attention to judicious 
antimicrobial use” (57) and in 2014 recommended the implementation of ASP in all acute care hospitals 
(58). 
The growing problem of the misuse of antibiotics has contributed to antibiotic resistance which is now a 
serious public health threat (59) and one of the great aims of ASP is to reduce the emergence of antibiotic 
resistant strains.  
An important strategy for the role of colistin in ASP is the  use of patient characteristics and optimizing 
doses based on pharmacokinetic and pharmacodynamics(56). 
Intravenous polymixins (e.g. colistin) are recommended against carbapenem-resistant bacteria that are 
sensitive only to polymixins in patients with HAP/VAP. A seven-day course is recommended; however, a 
shorter or longer duration may be required based on the clinical picture.(60) 
 
2.4 Summary of Literature Review 
 
The studies reviewed have shown efficacy with both low and high dose colistin with variable level of 
adverse effects. The gap in research is that there is no direct comparison of low and high dose colistin in 
the treatment of NP caused by colistin-only sensitive GNB. 
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CHAPTER 3 
 
MANUSCRIPT FOR SUBMISSION AND PUBLICATION 
 
3.1 Introduction 
 
This chapter describes the general findings and discussion of the results of the study and is represented in 
the form of a manuscript titled “Pharmacoeconomic model to compare the cost-effectiveness of low vs 
high dose colistin in the treatment of nosocomial pneumonia caused by Multi-Drug Resistant (MDR) 
gram negative Bacteria in Saudi Arabia”. This manuscript was submitted to the “International Journal of 
Clinical Pharmacy” for publication. 
 
The journal instructions to the author can be found at the following link: 
 
http://www.springer.com/medicine/internal/journal/11096?detailsPage=pltci_3137197 
 
 
 
 
 
 
The reference list is cited according to the instructions for authors as required by the IJCP. A complete 
reference list is included at the end of every chapter and according to the reference style of the University 
of KwaZulu Natal. 
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ABSTRACT 
 
Background 
Gram negative pathogens are increasingly resistant to common first line antibiotics and colistin is often 
the only medicine available. Limited information is available comparing the effectiveness and costs of 
low dose colistin(LDC) versus high dose colistin(HDC). Studies show efficacy with both and with 
variable levels of adverse effects. The absence of a definite dosing strategy makes a model comparing 
LDC and HDC invaluable in making decisions regarding the appropriate use of colistin. 
 
Objective 
This study was designed to evaluate the cost effectiveness of LDC versus HDC in the treatment of 
Pneumonia caused by colistin-only sensitive gram negative bacteria from the perspective of tertiary care 
hospital in Saudi Arabia. 
 
Setting 
300-bed tertiary care hospital in Saudi Arabia. 
 
Method 
A decision–analytic model using data from a retrospective review was developed comparing the costs and 
outcomes of treatment of pneumonia with LDC versus HDC. The model followed an average patient from 
initiation of treatment until clinical cure or failure.  
 
Main outcome measures 
The main outcomes were cure, nephrotoxicity, total direct costs per episode, cost per additional cure and 
cost per nephrotoxicity avoided. 
 
Results 
There was no significant difference between HDC and LDC with regards to clinical cure (30% vs. 21%; 
p=0.292). More patients experienced nephrotoxicity with HDC vs. LDC (30% vs. 8%; p= 0.004) 
With LDC the incremental costs per nephrotoxicity avoided was SAR -3056.28/nephrotoxic case 
prevented and the incremental cost effectiveness ratio was SAR -13894.66/nephrotoxic case prevented.  
Conclusion 
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LDC was not inferior to HDC in terms of clinical cure and had a lower incidence of nephrotoxicity 
resulting in significant cost avoidance. 
Keywords:  
"cost effectiveness”, “efficacy”, “colistin”, “pneumonia”, “gram negative” and “multi drug resistant”. 
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Introduction  
Nosocomial Pneumonia (NP) is defined as pneumonia that occurs after healthcare contact. NP 
encompasses hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (1,6). 
Rates of HAP due to multidrug-resistant gram-negative bacteria (MDR-GNB) have escalated in recent 
years and are a major concern(2). Gram negative pathogens are increasingly resistant to commonly used 
first line antibiotics and often colistin is the only medicine available against MDR-GNB. The incidence of 
VAP in developing countries ranges from 16.7 to 73.4 per 1,000 ventilator-days in adult ICUs (9,10). The 
effect of MDR bacterial infections have been studied and demonstrate an increase in overall costs (17). 
 
Various studies have reported on the effectiveness of high dose colistin (HDC) (21) and low dose colistin 
(LDC) (4,5). There are still no definite dosing recommendations and limited information is available 
about the comparative effectiveness of LDC versus HDC. Studies on the safety and efficacy of colistin 
abound both with HDC(24,38) and LDC (3–5). Studies have shown efficacy with both these doses with 
variable level of adverse effects, mainly nephrotoxicity which is one of the most commonly cited adverse 
effects of colistin treatment (18,26–28).  
 
There is convincing evidence of greater incidence of nephrotoxicity using higher doses of colistin.  
Falagas et al (27) reported nephrotoxicity that had a statistically significant dose dependent relationship.  
Nephrotoxicity was reported as 43% by Pogue et al (46), with greater nephrotoxicity with doses between 
3mg/kg/day and 4.9mg/kg/day. Chan et al (45) reported a much higher rate of colistin associated 
nephrotoxicity using doses between 2.5 and 5mg/kg/day.  
 
A model to compare LDC and HDC in the treatment of pneumonia caused by colistin-only sensitive 
MDR-GNB will assist clinicians in decision making. Given the reported efficacy of low dose colistin in 
the treatment of MDR GNB (3–5), greater nephrotoxicity with higher doses and the financial burden that 
NP places on the healthcare systems worldwide, the purpose of this study was to construct an economic 
model that will allow the comparison of LDC and HDC in the treatment of pneumonia caused by colistin-
only sensitive MDR GNB.  
 
Aim of the study 
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The aim of this study was to determine cost effectiveness of low dose colistin (less than 2.5mg/kg) versus 
high dose colistin (greater than 2.5mg/kg) dosed every 12 hours in the treatment of NP due to MDR-GNB 
using a decision analytic (DA) model. 
Ethical Approval 
The study was conducted in accordance with the principles of the Declaration of Helsinki and its 
amendments and in compliance with International Conference on Harmonization, Good Clinical 
Practices, and all applicable regulatory guidelines.  
Full ethical approval for the study was obtained from King Abdullah International Medical Research 
Centre (HAS-16-437780-10741) on 19 January 2016 (Annexure 1) and from the Humanities and Social 
Sciences Research Ethics Committee of the University of KwaZulu-Natal (HSS/0975/015M) on 29 
January 2016 (Annexure 2). 
 
Patient confidentiality was maintained always and no patient hospital numbers, names or date of 
birth/identification numbers were reported in the data sets. 
 
METHODS: 
Study design 
The design of this study was a retrospective analysis conducted at a 300-bed hospital in Saudi Arabia 
comparing the treatment of NP with low dose colistin versus high dose colistin. The study population 
consisted of all patients treated with colistin for Nosocomial Pneumonia caused by MDR-GNB at King 
Abdulaziz Hospital, AlHasa, Saudi Arabia. Patients in the low dose colistin group received less than 
2.5mg/kg and the high dose colistin group received greater than 2.5mg/kg administered every 12 hours. 
The commercial product used was Colomycin® containing 33mg colistin base per vial (30,000 
international units per mg) 
 
Definitions 
Multidrug–resistant gram negative bacteria for the purposes of this study are defined as bacteria resistant 
to aminoglycosides, anti-pseudomonas penicillins, carbapenems, cephalosporins and fluoroquinolones 
(61). 
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Clinical cure was defined as resolution of signs and symptoms of infection including absence of fever for 
a minimum of 72 hours and a white blood cell count below 12 000 cells/ mm
3
 
 
Nephrotoxicity was defined as an increase in serum creatinine by 26.52µmol/L or more within 48 hours or 
increase in serum creatinine to 1.5 times baseline or more within the last 7 days (30). 
 
Participants 
There was a total of 171 patients that received colistin during the study period.  After applying the 
inclusion and exclusion criteria 96 were evaluated. This included 63 and 33 in the LDC and HDC groups, 
respectively. 
 
Inclusion criteria 
The following patients were included in the study: 
1. Patient over 12 years old and receiving colistin for documented nosocomial pneumonia in ICU 
and Non-ICU wards 
2. Patients must have received colistin for colistin-only sensitive MDR-GNB infection 
3. Patients must have received colistin for at least 72 hours 
4. If a patient received more than one course of colistin within a single admission, only the first 
course was included 
 
Exclusion criteria 
The following patients were excluded from the study: 
1. age less than 12 years old 
2. patients treated only with inhaled colistin 
3. patients who did not receive colistin for at least 72 hours 
4. patients with moderate to severe renal impairment or received renal replacement therapy or 
dialysis 
 
Statistical Analyses 
 
In this study, two-sided significance was used for statistical analyses. All p values of 0.05 or less were 
considered statistically significant providing a 95% confidence interval. Dichotomous data were 
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compared using the Chi-Square test. Normally distributed continuous data are expressed as mean and 
standard deviation and compared using the Student’s t-test. Otherwise, values are presented as medians 
with ranges and compared using the Mann – Whitney U test. Quantitative variables were analyzed with 
the chi square test or Fischer’s exact test (two-tailed) when necessary. All data was entered in a database 
and SPSS 20.0 software package was used to analyze the data. 
Model Outcomes and Pharmacoeconomic Analyses 
The data was modelled using a decision analysis, considering the occurrence of NP with MDR-GNB, the 
two treatment alternatives (LDC versus HDC) and two outcomes (cure and no cure) as well as 
nephrotoxicity in each. Figure 1 shows the decision tree. Clinical outcomes (cure rate and nephrotoxicity 
rate) and the cost outcomes (total cost per patient) were calculated. Effectiveness was measured as rate of 
clinical cure and nephrotoxicity avoided. Probabilities of the different outcome parameters came from 
analysis of our retrospective study.  
Incremental cost (IC) was calculated as Cost of HDC - Cost of LDC. Average cost effectiveness ratio 
(CER) was calculated as C LDC⁄ E LDC for the LDC strategy and C HDC ⁄E HDC for the HDC strategy; 
where C = cost (SAR) and E= efficacy (cure or nephrotoxicity avoided)(62). Efficacy was defined as the 
probability of patients who experienced NP responded to the study medicine (defined as ‘cure’) and 
probability that nephrotoxicity would be avoided in patient treated with the study medicine.  Cost 
effectiveness was measured in terms of Incremental Cost Effectiveness Ratio (ICER). 
ICER was calculated using the following equation:  
(Cost of LDC) – (Cost of HDC) ⁄ (Efficacy of LDC) – (Efficacy of HDC)(62) 
A dominant strategy was defined as being less costly with increased efficacy (clinical cure) or with least 
toxicity (nephrotoxicity). 
Costing 
Direct costs for each treatment option were calculated considering the cost of medicines, ward costs, 
physician and consultant costs, nurse costs, laboratory costs and cost of colistin therapy. Direct non-
medical costs such as transportation; indirect non-medical costs such as lost income; and intangible costs 
such as pain are not considered since they are beyond the scope of the study. Cost of consumables and 
administration sets as well as costs for pharmacy staff were not included as they were assumed to be 
identical for the two arms (prepared and administered in the same manner). 
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Perspective and Timescale 
This economic analysis was conducted from the perspective of the payer King Abdulaziz Hospital. The 
study period was that of the treatment period being from initiation of colistin to treatment cure or failure.  
Discounting and currency 
Future costs were not included since the costs and benefits pertained to the time horizon of colistin 
treatment. Discounting was therefore not performed because the time-period was too short to show any 
significant contribution. The currency used was Saudi Arabian Riyal (SAR) (USD 1= SAR 3.77 as at 16 
November 2016, www.xe.com).  
Assumptions: 
Being a cost-effectiveness analysis, there were some assumptions made that could limit the 
generalizability of these results.  
Parameters for adverse reactions (ADRs) other than nephrotoxicity were not included because it was 
assumed to have non-significant contributions to the overall cost-effectiveness and because 
nephrotoxicity is the main adverse drug reaction affecting outcomes. Antibiotics used to treat other gram-
negative and gram-positive organisms were assumed to be equivalent between both groups and thus not 
included into the model. The costs of infection focused on NP due to Acinetobacter Baumannii (AB), 
Pseudomonas Aeruginosa (PA) and Klebsiella Pneumonia (KP) and any treatment costs associated with 
other infections were not accounted for in the model. 
RESULTS: 
Baseline characteristics: 
The baseline characteristics of the samples are summarized in Table 1.  The two groups did not differ 
significantly with regards to age (68.76 years and 67.08 years; p=0.7070), however, there was a 
significant difference with regards to weight (56.52 kg and 76.87 kg; p=<0.001) and gender (79 % and 
56% male; p=0.025) between the HDC and LDC groups, respectively. 
Comorbidities between the two groups were not significantly different in all respects except for 
malignancy (2 vs 0; p=0.048) for the HDC and LDC groups, respectively. The Charlson comorbidity 
index between the two groups (3.88 and 3.67; p=0.585) was not significantly different for the HDC and 
LDC groups, respectively.  
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There was no significant difference with respect to concomitant nephrotoxic medications (vancomycin, 
aminoglycosides, NSAIDs, ACEI/ARBS and furosemide) used in the two groups. The average duration 
of colistin treatment, average length of stay and location of patients within the hospital between the two 
groups was not significantly different. 
The two groups were significantly different in terms of the causative organism; AB (76% and 53%; 
p=0.037), PA (24% and 49%; p=0.018), for HDC and LDC, respectively. However, KP (6% and 9%; 
p=0.56) was not significantly different, for HDC and LDC, respectively. The average dose (mg) of 
colistin was 2.83+-0.50 and 1.52 +0.43 (p= 0.001) and the average duration of colistin treatment (days) 
was 12.76 +13.38 and 12.67 +12.51 (p= 0.974) in the HDC and LDC groups, respectively. 
  
Table 1 Characteristics of patients based on colistin dose group 
 High Dose  
Colistin  
(n=33) n (%) 
Low Dose  
Colistin  
(n=63) n (%) 
 
 
p-value 
Demographics  
Age in years (mean + SD) 68.76+20.61 67.08+20.77 0.707 
Weight in kg (mean + SD) 56.52 +17.42 76.870 +24.87 0.000 
Gender (Male) 26 (79) 35 (56) 0.025 
Gender (female) 7 (21) 28(44) 0.025 
Comorbidities  
Charleston Comorbidity Score (SD) 3.88+1.71 3.67+1.85 0.585 
COPD 4 4 0.331 
CHF 2 9 0.220 
malignancy 2 0 0.048 
Endocrine 8 17 0.771 
Sepsis  16(48) 23(36) 0.256 
UTI 4(12) 6(9) 0.692 
 
Location of patient 
 
Patients admitted to ICU 9 (27) 20 (32) 0.650 
Patients admitted to general wards 24(73) 43(68) 0.650 
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Table 1 (continued) 
 
 
 
High Dose  
Colistin  
(n=33) n (%) 
Low Dose  
Colistin  
(n=63) n (%) 
 
 
p-value 
 
Colistin treatment 
 
 
Average Colistin dose (mg/kg) 2.83+0.50 1.52 +0.43 0.001 
Average duration of colistin treatment (days) 
Average length of stay (days) 
 
12.76 +13.38 
124.40 +202.70 
 
12.67 +12.51 
113.10+340.80 
 
0.974 
0.861 
 
Concomitant nephrotoxic meds  
Vancomycin 18(55) 46 (73) 0.068 
Aminoglycosides 5(15) 4(6) 0.160 
NSAID 11(33) 29 (46) 0.231 
ACEI/ARBS 4(12) 10 (16) 0.621 
Furosemide 
 
Causative organisms 
AB (n=59) 
PA (n=39) 
KP (n=8) 
15(45) 
 
 
25 (76) 
8 (24) 
2 (6) 
36(57) 
 
 
34 (53) 
31 (49) 
6 (9) 
0.276 
 
 
0.037 
0.018 
0.56 
 
Abbreviation: COPD = Chronic Obstructive Pulmonary Disease; CHF = Congestive Failure; UTI= 
Urinary Tract Infection; ICU = Intensive Care Unit; NSAID = Non-Steroidal anti- inflammatory Drugs; 
ACEI = Angiotensin Converting Enzyme Inhibitor; ARBS = Angiotensin II receptor blockers; AB = 
Acinetobacter Baumannii; PA = Pseudomonas Aeruginosa; KP = Klebsiella Pneumoniae.  
a
Mean values (+ SD) and the number of cases with their relevant percentage in brackets.  
 
Efficacy and safety outcomes (Table 2) 
Table 2: Outcomes 
 High Dose  
Colistin      
 (n=33) n (%) 
Low Dose  
Colistin 
(n=63) n (%) 
 
p-value 
 
Clinical Cure  
 
        10(30) 
 
13(21) 
 
0.292 
 
Nephrotoxicity 
 
        10(30) 
 
5(8) 
 
0.004 
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Clinical cure analysis 
HDC was associated with a greater probability of clinical cure (30%) compared to LDC (21%), however 
the difference was not found to be significant (p=0.292). 
Nephrotoxicity analysis 
Safety was measured as number of incidents of nephrotoxicity avoided by comparing treatment with HDC 
and LDC. There was a significant difference in the incidence of nephrotoxicity, 30% and 8% (p= 0.004) 
between the HDC and LDC groups, respectively. Using this data, we calculated the percentage of patients 
in which nephrotoxicity was avoided with HDC (100-30=70%) and with LDC (100-8=92%).  
Multivariate Analysis of outcomes (Table 3) 
Multivariate analysis revealed significant nephrotoxicity within high dose colistin arm (p- value 0.011). 
Multivariate analysis further revealed that high dose colistin did not achieve better cure compared to low 
dose colistin (OR 1.74, 95% CI 0.63 – 4.80; P= 0.283). However, they have a greater chance of 
developing nephrotoxicity (OR 4.71, 95% CI 1.42 – 15.67; p=0.011). 
 
Table 3: Multivariate Analysis of Outcomes 
 OR 95% CI p-value 
 
Clinical Cure  
 
  1.74 
 
0.63 – 4.80 
 
0.283 
 
Nephrotoxicity 
 
  4.71 
 
1.42 – 15.67 
 
0.011 
 
Costs 
Average total direct costs per episode of colistin treatment in the LDC and HDC groups were SAR 
24718.42 and SAR 27775.25, respectively. The main components of costs were days of ICU stay (18.8% 
and 24.37%) and physician visits (20.5% and 18.37%) for patients in LDC and HDC groups, respectively. 
Costs were obtained using data from hospital resources utilized (Table 4) and costs from the hospitals 
business center December 2016 price list (Table 5). Direct costs for the treatment duration in both arms 
listed in Table 6. 
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Table 4: Hospital Resources utilized 
        High Dose  
       Colistin    
   (n=33) (SD) 
   Low Dose 
   Colistin 
    (n=63) (SD) 
 
p-value 
Number of ICU consultant visits (mean)  12.42+ 12.61  4.81 + 6.61 0.006 
Number of GW consultant visits (mean) 11.33+ 13.86 14.29 + 14.65 0.425 
Number of physician visits (mean) 25.52 + 26.77 25.33 + 25.03 0.974 
Number of ICU Nurse visits 4.52 + 9.56 3.11 + 5.96 0.379 
Number of GW nurse visits    8.5 + 12.94 9.21 + 13.53 0.808 
Number of ICU days           4.52 + 9.56 3.11 + 5.96 0.379 
Number of GW days 12.76 + 13.39        12.44 + 12.62 0.910 
Number of CBC tests 12.76 + 13.39        12.67 + 12.51 0.974 
Number of basic screens 3.19 + 3.35 3.17 + 3.13 0.978 
Number of renal panels 
Number of lab cultures 
4.25 + 4.46 
1.56+ 1.24 
4.22 + 4.17 
2.44+ 1.85 
0.975 
0.019 
________________________________________________________________________ 
Key: ICU=Intensive Care Unit; GW=General ward; CBC=Complete Blood Count.  
Results are expressed as mean + standard deviation 
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Table 5: Costs 
Business Center Pricing (December 2016)                  _Cost (SAR)        
Cost of ICU stay/day                 1,500 
Cost of general ward stay/day             500 
Cost of consumables in ICU/day        250 
Cost of consumables in General Ward /day       50 
Cost of ICU physician consultation                      1,000 
Cost of General Ward physician consultation     200 
Cost of ICU nurse/day          300 
Cost of General ward nurse/day        100 
Cost of CBC          80 
Cost of Basic Screen       200 
Cost of Renal Panel       240 
cost of tracheal culture                     150 
cost of throat culture       150 
cost of sputum culture       150 
cost of respiratory culture                    190 
cost of tracheal culture        150 
________________________________________________________________ 
Key: ICU=Intensive Care Unit; CBC=Complete Blood Count 
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Table 6: Mean Direct Cost of treatment per patient 
________________________________________________________________________________ 
   High dose colistin  Low dose colistin  
   (n=33) mean +SD (n=63) mean +SD          p-value 
________________________________________________________________________________ 
GW consultant visits   2069.54+ 1972.18 1821.38+ 1788.57  0.535 
ICU consultant visits   3733.64+ 7804.30  2421.05+ 4252.24  0.288 
GW days   4121.21+ 6412.91 4738.10+ 6759.02   0.667 
Staff physician visits   5103.03+ 5354.47 5066.67+ 5007.35  0.974 
ICU days   6772.73+ 14344.04 4666.67+ 8939.76  0.379 
Renal panel   1020.61+ 1070.89 1013.33+ 1001.47  0.974 
GW nurse visits   1275.76+ 1338.62 1266.67+ 1251.84  0.974 
ICU nurse visits   1354.55+ 2868.81 933.33+ 1797.95  0.379 
Basic screen   318.94+ 334.65  317.02+ 312.69   0.978 
CBC tests   1020.61+ 1070.89 1013.33+ 1001.47  0.974 
Cost of colistin   756.16+ 495.83  1129.91+ 847.51  0.022 
Laboratory cultures   228.48+ 189.56  340.48+ 286.65   0.046 
Mean Total costs   27775.24+ 31893.63 24718.42+ 21166.64  0.576 
Key: ICU=Intensive Care Unit; GW= General Ward; CBC=Complete Blood Count 
 
Cost effectiveness  
Based on the efficacy and safety outcomes and the costs attached to each outcome, it was possible to 
calculate the IC, CER and ICER (Tables 7). When LDC and HDC were compared using ICER, LDC was 
the dominant strategy compared to HDC in terms of number of incidents of nephrotoxicity avoided (ICER 
= -SAR 13, 894.66 per nephrotoxicity avoided). 
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Table 7: Cost effectiveness analysis- Nephrotoxicity avoided 
Strategy  Cost  Incremental cost effect  CER  ICER 
High dose colistin 27775.24    0.70  39678.92 
Low dose colistin 24718.42  -3056.82  0.92  26867.84       -13894.66 
Sensitivity Analysis 
To reflect the uncertainty inherent in the analysis, a series of univariate (one-way) sensitivity analyses 
was performed for all parameters in the model to assess the effect of varying certain parameters by 25%. 
Changes in the incremental costs are depicted in a tornado diagram (Figure 2). Analyses were performed 
using Microsoft Excel (2003; Microsoft Corp, Redmond, WA, USA). The incremental costs per 
nephrotoxicity avoided was most sensitive to the cost of staff physician visits, ICU days and general ward 
days. However, varying these parameters by 25% did not change the conclusions. 
Figure 2 – Sensitivity analysis- Tornado Diagram 
Key: icu= intensive care unit; gw= general ward; cbc= complete blood count 
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Table 8: One way sensitivity analysis for low dose colistin (Incremental cost=SAR3056) 
Parameter    25% decrease  25% increase    % change 
Cost of staff physician visits  1789.33  4322,67  41.48% 
Cost of general ward days  1871.48  4240.52  38.79% 
Cost of ICU days   1889.33  4223.49  38.20% 
Cost of ICU consultant visits  2450.74  3661.26  19.83% 
Cost of general ward consultant visits 2600.65  3511.35  14.93% 
Cost of general ward nurse visits 2739.33  3372.67  10.39% 
Cost of colistin    2773.52  3338.48  9.27% 
Coat of renal panel   2802.67  3309.33  8.32% 
Cost of CBC tests   2802.67  3309.33  8.32% 
Cost of ICU nurse visits   2822.67  3289.33  7.66% 
Cost of lab cultures   2973.26  3138.74  2.73% 
Cost of basic screen   2976.74  3135.26  2.62% 
 
DISCUSSION: 
Several studies have reported on the efficacy of LDC in the treatment of MDR GNB(3–5) and because the 
financial burden that NP places on healthcare systems worldwide, we constructed an economic model to 
compare LDC and HDC. 
Our study design was similar to that used by Bounthavong M, et al.(49) in their cost effectiveness 
analysis of linezolid versus vancomycin in MRSA complicated skin and soft tissue infection. Whereas the 
authors of that study used past clinical trials to obtain the different probability parameters, our 
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study utilized the probabilities from the retrospective analysis of patients treated at our institution during 
the study period. The outcomes of our study were also calculated in the same manner as that utilized 
by Bounthavong M, et al.  
A German cost effectiveness analysis of linezolid vs vancomycin in NP conducted by De Cock E, et al. 
(50) used a similar methodology to Bounthavong M, et al. The German authors, however, used a Delphi 
panel to supplement the clinical trial data as well as economic data when these were no available from the 
trials. Conditions of clinical trials are likely to be different from real life practice and our study used real 
life data. 
The findings of this study show that there is no significant difference in clinical cure between HDC and 
LDC (30% vs 21%; p=0.292). The low clinical cure rates are similar to those of Kalin et al (4) but much 
lower than those obtained by Yilmaz et al. (3)  
Our findings also show that LDC produced significantly less nephrotoxicity than HDC (8% vs 30%; 
p=0.004). The low incidence of nephrotoxicity with LDC is similar to that of Yilmaz et al  (3) who 
reported an incidence of 7.7% as well as those of Zaidi et al (5) who reported a rate of 12.8% in patients 
receiving LDC.  
Interpretation of the ICER per nephrotoxicity avoided is appropriate considering that the costs and 
benefits relate to the model time horizon of colistin treatment.  
The use of LDC would provide the same efficacy as HDC and realize a saving of SAR 13, 894.66 due to 
nephrotoxicity avoided.  
Limitations 
This was a retrospective single center study and this only provides insight into colistin use for NP at King 
Abdulaziz Hospital. A randomized controlled study would be preferred however limitations of resources 
did not warrant same. Due to the limited number of evaluable patients, the small sample size included in 
this study did not provide the required power. A larger sample would allow for more robust results. 
 
Resistance to colistin is a major concern since this is frequently the only available medicine against 
MDR-GNB. Colistin resistance has been reported to be due to inadequate colistin dosing(63). Higher 
doses seem to be more beneficial but no optimal dose has yet been defined. The effect of resistance was 
59 | P a g e  
 
not investigated in our model and future studies should investigate whether resistance patterns would 
change the outcomes. 
There is a possibility of selection bias since patients in the low dose group were of higher weight 
compared to the low dose group and it is possible that the physician prescribed lower doses of colistin for 
these patients and higher doses for patients in the high dose group. 
This study defined nephrotoxicity using change in serum creatinine, as this was the most readily available 
in patient’s charts. The use of  RIFLE criteria would have been ideal as this is now recognized as the 
standard diagnostic criteria(30).  The RIFLE criteria used three severity categories, namely risk, injury 
and failure; and two outcome categories, complete loss of kidney function and end-stage kidney disease.  
Parameters for adverse reactions (ADRs) other than nephrotoxicity were not included because it was 
assumed to have non-significant contributions to the overall cost-effectiveness and because 
nephrotoxicity is the main adverse drug reaction affecting outcomes.  
Antibiotics used to treat other gram-negative and gram-positive organisms were assumed to be equivalent 
between both groups and thus not included into the model. Inclusion of other treatment costs could affect 
the results. 
 
CONCLUSION: 
To the best of the authors’ knowledge, this is the first study undertaken in exploring the cost effectiveness 
of LDC versus HDC in the treatment of NP. Despite the assumptions and limitations mentioned, this 
study provides a deeper insight into the use of colistin in NP. Based on the results of this study, KAH 
should adopt the LDC strategy for treatment of NP caused by MDR-GNB while taking cognizance of 
local resistance patterns. Further studies are needed to investigate the true impact of using low dose 
colistin on healthcare costs.  
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CHAPTER 4 
CONCLUSION 
 
4.1 INTRODUCTION 
This study was conducted to evaluate the safety and efficacy of low dose colistin versus high dose colistin 
and construct a cost effectiveness analysis comparing the two strategies. 
 
4.2 Conclusions drawn from the study findings 
 
There was no significant difference in efficacy between LDC and HDC in the treatment of NP due to 
MDR-GNB (21% vs 30%, respectively; p=0.292). Although the researchers could not find any studies 
comparing low dose and high dose colistin directly, many studies have reported on the efficacy of both 
doses in the treatment of various infections(3,4).  
 
The incidence of nephrotoxicity in this study is much less with LDC than with HDC (8% vs 30%, 
p=0.004). These finding are similar to other studies reporting on incidence of colistin induced 
nephrotoxicity(3–5,43,45). Thus, LDC is more cost effective than HDC for the treatment of NP due to 
MDR-GNB. This study also showed that the factors that contribute most to the overall cost of treatment 
are ICU days and cost of physician visits. The incremental costs per patient cured and incremental costs 
per nephrotoxicity avoided were most sensitive to the cost of ICU days, physician visits and consultant 
visits. Sensitivity analyses did not change the outcomes though. Results of this study further showed that 
although LDC and HDC acquisition costs vary significantly, the mean total costs of treatment do not 
differ significantly, indicating that medicine costs are a small component of the overall cost of treating 
NP.   
 
 
4.3 Significance of the study 
 
Pneumonia due to MDR-GNB places a great drain on hospital resources. There is also a lack of an 
optimal dosing strategy for colistin. Furthermore, high dose colistin has been associated with a higher 
incidence of nephrotoxicity. To the best of the authors knowledge there are no other studies investigating 
the cost effectiveness of LDC versus HDC. This study intended to fill that gap. 
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4.4 Recommendations 
LDC is as effective as HDC in the treatment of NP due to MDR-GNB and has a lower incidence of 
nephrotoxicity. LDC is more cost effective and should therefore be the considered for the treatment of NP 
due to MDR-GNB. 
KAH should adopt the LDC strategy for treatment of NP caused by MDR-GNB while taking 
cognizance of local resistance patterns using the hospital antibiogram. 
Given the limitations of this study, clinical studies with larger numbers are required to confirm these 
results and investigate the true impact of using LDC in order for these results to be generalizable. 
 
4.5 Chapter summary 
 
This chapter highlighted the conclusions of the study while describing the strengths and weaknesses and 
providing recommendations for change of treatment guidelines and future research. 
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